PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
PSMA-OLIGO-PRO is a multicenter ambispective observational real-world registry evaluating outcomes after PSMA PET-guided progression-directed radiotherapy for oligoprogressive prostate cancer. The registry includes retrospectively identified patients treated before June 26, 2026 and prospectively enrolled patients from June 26, 2026 onward. Eligible patients have metastatic hormone-sensitive or castration-resistant prostate cancer, are receiving active systemic therapy, and develop a limited number of new or regrowing lesions while the remaining disease sites are controlled. Oligoprogression is primarily defined by PSMA PET/CT or PSMA PET/MR, with MRI used when clinically appropriate, particularly for intraprostatic, local, or prostate-bed progression. Participants are not assigned to treatment by the registry protocol. All imaging, systemic therapy, radiotherapy modality, dose, fractionation, and follow-up decisions are made by treating physicians as part of routine clinical care. Progression-directed radiotherapy may include stereotactic body radiotherapy for nodal, bone, visceral, or local lesions, moderately hypofractionated external beam radiotherapy when clinically selected, and brachytherapy when appropriate for intraprostatic, prostate-bed, or selected metastatic oligoprogressive lesions. The registry evaluates whether treating all identifiable oligoprogressive lesions can delay escalation to a new systemic therapy line, preserve the oligometastatic state, maintain local control, and provide acceptable safety in contemporary PSMA PET-guided practice.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rozpoznany rak prostaty z przerzutami
- •Otrzymywanie aktywnego leczenia systemowego w czasie pojawiania się nowych ognisk
- •Do pięciu nowych lub ponownie rosnących ognisk choroby wykrytych w badaniu PSMA PET
- •Pozostałe ogniska choroby są kontrolowane
- •Planowana lub wykonana radioterapia skierowana na wszystkie ogniska pogorszenia
✗ Disqualifies
- •Rozpowszechniona choroba (więcej niż pięć nowych ognisk)
- •Radioterapia wykonana jedynie w celu łagodzenia objawów, a nie kontroli choroby
- •Brak wystarczających danych medycznych i obrazowych do oceny wyników
- •Inne warunki, które w opinii lekarza czynią udział w badaniu niewłaściwy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Affidea Nu-Med Cancer Diagnostics and Therapy Center
Zamość, Poland
Trial contact
Mateusz Bilski, MD, PhD
Paulina Kleban
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.